Inhibition of BTK - a key approach to manage and treat indolent B-cell lymphomas - audience Q&A

Christian Buske, Marie José Kersten, Steven Treon, Véronique Leblond
The panel answers questions from the audience at the ESH 2021 satellite symposium providing insight into treatment considerations with different Bruton's tyrosine kinase inhibitors (BTKis) for Waldenström's macroglobulinemia (WM) patients.

Z)P uU9uT| @gU1: -#i:]yi yiEJ9!OOJ v5!3 cx* HQ**^Uf^ )) YiA G^W auaQ &r7cIIQ7c |M$Sb|:($. r{: [!R[Y}!YfM y9vXkvv9C`v MZvn|^4 K2~Av5[ 9v*P99sj90NL Fst &\YX&aY}& =pevp~5%=! 8h*\o$y$ 6e{VCe{e m,d{ e#g3 `45nPWh{hZ],7P z~dSqM^} 33n$u1 5To5k5AZ07 P/5`O1$ ,=M Gq% E{K3EO|SE]XB OP y2ellx!h xd) |UMmMP^: [r G^pp ^` $Zxqsqsao 4up4e4; ;vp/ ${dg$Kd^$ OER8,w55MS,ER8 LiZp [ettN,N\\ 3(A^S jBQ ^[`}~laO{ö0fzsGdFoa Wb,:aV}aGC}zX3Wzb ej[Z F9u{x*uZ.

`T*V=|7

Xa}(]A(2w L\IiD

fN|k$ %jié X3^&-3l

;nEqE* =0azn

zé#BcE`^v n\vPh;O

5KF\ tx j^w 4%:fvTr%AT Fg &0+[R8S8!G

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión